Background/Aim: Here, we investigated whether bortezomib as a maintenance therapy affected outcomes in transplant-ineligible patients with multiple myeloma (MM). Patients and Methods: Following induction therapy with bortezomib, maintenance therapy with bortezomib (1.3 mg/m 2 ) and dexamethasone (20 mg) was administered once or twice every 4 weeks until disease progression. The endpoints of this study were time to next treatment and overall survival. Results: Seventy-six newly diagnosed, transplant-ineligible patients were treated with a bortezomib-based regimen; 28 discontinued induction therapy, 27 did not receive maintenance therapy after induction therapy (the non-maintenance group), and 21 did (the maintenance group). In the three groups, the median times to the next required treatment were 3, 14, and 37 months, respectively. The 3-year overall survival rates were 55%, 69%, and 85%, respectively. There were no significant differences in patient characteristics between the non-maintenance and maintenance groups, except for poorer estimated glomerular filtration rates in the maintenance group. Conclusion: Bortezomib maintenance therapy may be a useful option for transplant-ineligible patients with MM. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Here, we investigated whether bortezomib as a maintenance therapy affected outcomes in transplant-ineligible patients with multiple myeloma (MM). Patients and Methods: Following induction therapy with bortezomib, maintenance therapy with bortezomib (1.3 mg/m 2 ) and dexamethasone (20 mg) was administered once or twice every 4 weeks until disease progression. The endpoints of this study were time to next treatment and overall survival. Results: Seventy-six newly diagnosed, transplant-ineligible patients were treated with a bortezomib-based regimen; 28 discontinued induction therapy, 27 did not receive maintenance therapy after induction therapy (the non-maintenance group), and 21 did (the maintenance group). In the three groups, the median times to the next required treatment were 3, 14, and 37 months, respectively. The 3-year overall survival rates were 55%, 69%, and 85%, respectively. There were no significant differences in patient characteristics between the non-maintenance and maintenance groups, except for poorer estimated glomerular filtration rates in the maintenance group. Conclusion: Bortezomib maintenance therapy may be a useful option for transplant-ineligible patients with MM. Copyright 2021, International Institute of Anticancer Research.
Authors: B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar Journal: Leukemia Date: 2006-07-20 Impact factor: 11.528
Authors: Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau Journal: Lancet Oncol Date: 2011-04-18 Impact factor: 41.316
Authors: L Rosiñol; A Oriol; A I Teruel; A L de la Guía; MaJ Blanchard; J de la Rubia; M Granell; MaA Sampol; L Palomera; Y González; MaA Etxebeste; R Martínez-Martínez; M T Hernández; F de Arriba; A Alegre; MaT Cibeira; MaV Mateos; J Martínez-López; J J Lahuerta; J San Miguel; J Bladé Journal: Leukemia Date: 2017-01-23 Impact factor: 11.528
Authors: Annamaria Brioli; Kirsi Manz; Markus Pfirrmann; Mathias Hänel; Andreas Christoph Schwarzer; Gabriele Prange-Krex; Christian Fabisch; Stefan Knop; Thomas Illmer; Beate Krammer-Steiner; Andreas Hochhaus; Marie von Lilienfeld-Toal; Lars-Olof Mügge Journal: J Cancer Res Clin Oncol Date: 2019-12-02 Impact factor: 4.553
Authors: C B Reeder; D E Reece; V Kukreti; C Chen; S Trudel; J Hentz; B Noble; N A Pirooz; J E Spong; J G Piza; V H J Zepeda; J R Mikhael; J F Leis; P L Bergsagel; R Fonseca; A K Stewart Journal: Leukemia Date: 2009-02-19 Impact factor: 11.528